our constellation

Our lead product candidate, topical CGS-200-5, is being developed for the management of osteoarthritis (OA) and has successfully completed a Phase 2 clinical study for pain due to knee OA.   PRL-02 is currently in Investigational New Drug (IND)-enabling studies for prostate cancer and will begin clinical development in 2021.  An earlier-stage program showing promise is PRL-01, in late-stage preclinical development for herpes virus infections.